Medical technology company Medtronic announced on Wednesday that it has entered into an agreement with health care product provider Henry Schein Medical to exclusively distribute certain diabetes products to primary care doctors in the U.S. This partnership should help bring Medtronic devices to people with type 2 diabetes whose primary care physicians are responsible for their diabetes management. Medtronic is headquartered in Dublin but its diabetes division is based in Northridge. Some of the products that are offered in the Schein agreement are the i-Port Advance, a port that allows a person to inject insulin without having to puncture the skin each shot, and the iPro 2 Professional Continuous Glucose Monitoring system, a device that collects blood sugar data. “Solutions such as the iPro2 Professional CGM enable physicians to easily gather valuable insights to make educated therapy decisions and improve patient coaching, which can lead to better control for people with type 2 diabetes,” Laura Stoltenberg, general manager of non-intensive diabetes therapies at Medtronic, said in a statement. Henry Schein Medical is a division of Henry Schein Inc. in Melville, N.Y.
